December 20, 2017 / 12:48 PM / 6 months ago

BRIEF-Loxo Oncology Initiates Rolling Submission Of NDA To U.S. FDA For TRK Fusion Cancers Treatment

Dec 20 (Reuters) - Loxo Oncology Inc:

* LOXO ONCOLOGY INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR LAROTRECTINIB FOR THE TREATMENT OF TRK FUSION CANCERS

* LOXO ONCOLOGY INC - COMPANY EXPECTS TO COMPLETE NDA SUBMISSION IN EARLY 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below